Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide.
Pioglitasoon ei põhjustanud LDL- kolesterooli taseme statistiliselt olulist tõusu, võrreldes platseeboga, kuid metformiini ja gliklasiidiga täheldati selle langust.